Peripheral Neuropathic Pain
Conditions
Interventions
The alternative drug of Pregabalin approved to control pain is limited to Mirogabalin. And administration of Pregabalin is finished at enrollment.
At the time, regimen of Mirogabalin is as written be
Sponsors
Kimura Yoshiyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with Peripheral Neuropathic Pain. 2) Patients who is administrated Pregabalin for more than 28 days at enrollment of the study. 3) Patients with more than 40mm of VAS at informed consent and enrollment. 4)Patients with 20 years old or older at enrollment. 5)Patients who give their voluntary Written consent to participate in the study, also patients who are able to understand the procedure of the clinical study and answer a question appropriately.
Exclusion criteria
Exclusion criteria: 1) Patients who have past history of hypersensitivity to ingredients of Mirogabalin and Pregabalin. 2) Patients who have difficuly participating in the study due to severe complication of Liver Disease, Kidney Disease and Heart Disease. 3) Patients with creatinine clearance less than 30mL/min by Cockroft-Gault Equation at enrollment. 4) Pregnancy patients or patients who have possibility of pregnancy. 5) Nursing mothers. 6) Patients who are inappropriate for participation in the study for other reason in the opinion of the investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of occurrence of Somnolence, Dizziness and Peripheral edema from the enrollment to the end of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Amount of the change of pain intensity(VAS) from the enrollment to the end of the study | — |
Contacts
Public ContactHiroshi Yabe
EP-CRSU CO., LTD
Outcome results
None listed